Aidea Pharma: The full text of the 96-week study on Fubangde® SPRINT was published in BMC Medicine

Zhitong
2025.10.11 00:13

On October 11th, Aidea Pharma announced that the company's independently developed China's first "three-in-one" single-tablet combination innovative drug, the next-generation non-nucleoside combination formulation AINOMITE, has had its key Phase III clinical research results published in full in the flagship medical journal BMC Medicine, under the global academic publishing giant Springer Nature. This journal is a top-tier journal in the JCR and the Chinese Academy of Sciences' Zone 1, with a 5-year impact factor of 9.4. In addition, the influence of this publication has currently surpassed that of imported similar products

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.